Author:
Drummond David,Roy Charlotte,Cornet Matthieu,Bucher Julie,Boussaud Véronique,Pimpec-Barthes Françoise Le,Pontailler Margaux,Raisky Olivier,Lopez Vanessa,Barbanti Claudio,Guillemain Romain,Renolleau Sylvain,Grimaud Marion,Oualha Mehdi,de Saint Blanquat Laure,Sermet-Gaudelus Isabelle
Abstract
Abstract
Background
Children with advanced pulmonary disease due to cystic fibrosis (CF) are at risk of acute respiratory failure due to pulmonary exacerbations leading to their admission to pediatric intensive care units (PICU). The objectives of this study were to determine short and medium-term outcomes of children with CF admitted to PICU for acute respiratory failure due to pulmonary exacerbation and to identify prognosis factors.
Methods
This retrospective monocentric study included patients less than 18 years old admitted to the PICU of a French university hospital between 2000 and 2020. Cox proportional hazard regression methods were used to determine prognosis factors of mortality or lung transplant.
Results
Prior to PICU admission, the 29 patients included (median age 13.5 years) had a severe lung disease (median Forced Expiratory Volume in 1 s percentage predicted at 29%). Mortality rates were respectively 17%, 31%, 34%, 41% at discharge and at 3, 12 and 36 months post-discharge. Survival rates free of lung transplant were 34%, 32%, 24% and 17% respectively. Risk factors associated with mortality or lung transplant using the univariate analysis were female sex and higher pCO2 and chloride levels at PICU admission, and following pre admission characteristics: home respiratory and nutritional support, registration on lung transplant list and Stenotrophomonas Maltophilia bronchial colonization.
Conclusion
Children with CF admitted to PICU for acute respiratory failure secondary to pulmonary exacerbations are at high risk of death, both in the short and medium terms. Lung transplant is their main chance of survival and should be considered early.
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. Elborn JS. Cystic fibrosis. Lancet Lond Engl. 2016;19(10059):2519–31.
2. Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2019.
3. Davis PB, di Sant’Agnese PA. Assisted ventilation for patients with cystic fibrosis. JAMA. 1978;239(18):1851–4.
4. Vedam H, Moriarty C, Torzillo PJ, McWilliam D, Bye PTP. Improved outcomes of patients with cystic fibrosis admitted to the intensive care unit. J Cyst Fibros off J Eur Cyst Fibros Soc. 2004;3(1):8–14.
5. Ellaffi M, Vinsonneau C, Coste J, Hubert D, Burgel PR, Dhainaut JF, et al. One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis. Am J Respir Crit Care Med. 2005;171(2):158–64.